文献速递艾滋病与性传播感染病毒性肝炎

整合酶抑制剂累积暴露与代谢因素可独立预测HIV感染者重度肝脂肪变

Cumulative exposure to integrase inhibitors and metabolic factors as independent predictors of severe hepatic steatosis in people with HIV.
PubMed 文献 · J Antimicrob Chemother · 2026-01-01

这项单中心横断面研究纳入265例意大利HIV感染者,用振动控制瞬时弹性成像评估肝脂肪变与纤维化。多因素分析显示,整合酶抑制剂累积暴露每年aOR 1.19、BMI每kg/m2 aOR 1.45、每日饮酒aOR 2.41、LDL每+10 mg/dL aOR 1.20独立预测重度脂肪变(S3);病毒学抑制与肝硬度降低相关。

要点

  • 整合酶抑制剂累积暴露每年使重度肝脂肪变风险增加(aOR 1.19)。
  • BMI、每日饮酒和LDL胆固醇也是重度脂肪变的独立预测因素。
  • HIV-RNA<50 copies/mL与肝硬度显著降低相关(平均变化-1.61 kPa)。

核心结论

  • HIV感染者中肝脂肪变和纤维化高度流行,整合酶抑制剂累积暴露与代谢因素可能驱动重度脂肪变并加速纤维化损伤。
  • 有效病毒学抑制可显著降低纤维化风险,应把严格代谢监测和生活方式干预纳入长期照护方案。

研究设计与样本

  • 单中心横断面研究,评估意大利学术医学中心265例HIV感染者,中位年龄53.9岁,89.4% HIV-RNA<50 copies/mL,中位CD4计数758 cells/mm3。
  • 用振动控制瞬时弹性成像评估脂肪变(CAP,dB/m)和纤维化(kPa),并通过结构化问卷调查生活方式。

主要发现

  • 中重度脂肪变(S2-S3)占49%,重度脂肪变(S3)占28.5%。
  • 多因素分析中,重度(S3)脂肪变的独立预测因素包括整合酶抑制剂累积暴露较长(aOR 1.19/年,P=0.002)、BMI较高(aOR 1.45/kg/m2,P<0.001)、每日饮酒(aOR 2.41,P=0.031)和LDL胆固醇较高(aOR 1.20/+10 mg/dL,P=0.003)。
  • 规律体力活动与较低CAP相关;较高CAP值与肝硬度增加独立相关(每+10 dB/m平均变化+0.07 kPa,P=0.016)。
  • 病毒学抑制(HIV-RNA<50 copies/mL)与肝硬度降低显著相关(平均变化-1.61 kPa,P=0.001)。

临床怎么用

  • 对长期使用整合酶抑制剂的HIV感染者应定期评估肝脂肪变,并同步监测BMI、LDL胆固醇和饮酒情况。
  • 将生活方式干预(规律体力活动、限酒)和代谢管理整合进HIV感染者长期照护流程。
  • 维持HIV-RNA<50 copies/mL有助于降低肝纤维化风险。

局限性

  • 单中心横断面设计,无法推断因果关系。
  • 研究人群为意大利学术医学中心队列,外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The progressive ageing of people living with HIV (PLWH) has increased hepatic and metabolic comorbidities. OBJECTIVES: This study evaluates the impact of HIV-related, metabolic and behavioural factors on hepatic steatosis and fibrosis development using vibration-controlled transient elastography (VCTE). METHODS: This is a single-centre cross-sectional study evaluating an Italian cohort of PLWH at an academic medical centre. Steatosis (via CAP, dB/m) and fibrosis (kPa) were assessed using VCTE. Lifestyle habits were investigated through a structured questionnaire. Factors associated with severe steatosis (S3) and with fibrosis were analysed. RESULTS: Overall, 265 patients were included (median age 53.9 years; 89.4% with HIV-RNA < 50 copies/mL; median CD4 count 758 cells/mm3). Moderate-to-severe steatosis (S2-S3) affected 49% of the cohort (S3: 28.5%). In multivariate analysis, independent predictors of severe (S3) steatosis were longer cumulative integrase inhibitor (InSTI) exposure (aOR 1.19/year, P = 0.002), higher BMI (aOR 1.45 per kg/m2, P < 0.001), daily alcohol consumption (aOR 2.41, P = 0.031) and higher LDL cholesterol (aOR 1.20 per +10 mg/dL, P = 0.003). Regular physical activity was associated with lower CAP. Higher CAP values showed an independent association with increased liver stiffness (mean change +0.07 kPa per +10 db/m, P = 0.016), while virological suppression (HIV-RNA < 50 copies/mL) was significantly associated with reduced liver stiffness (mean change -1.61 kPa, P = 0.001). CONCLUSIONS: Hepatic steatosis and fibrosis are highly prevalent in PLWH. Cumulative InSTI exposure and metabolic factors may drive severe steatosis, which may accelerate fibrotic damage, whereas effective virological suppression can significantly lower fibrosis risk. Strict metabolic monitoring and lifestyle interventions should be integrated into PLWH long-term care protocols.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Panza F, Crispo M, Sambo M, et al. Cumulative exposure to integrase inhibitors and metabolic factors as independent predictors of severe hepatic steatosis in people with HIV. J Antimicrob Chemother. 2026. PMID: 42904454. doi:10.1093/jac/dkag351

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。